01 / CAPSID
Capsid-modified vector construction
Fiber and capsid engineering for tropism retargeting, including knobless, chimeric, peptide-incorporated, and antibody-modified designs.
Adenoviral Vector Systems Resource
Adenoviral Vector Systems: Ad5, Ad5/35, RGD, and Helper-Dependent
Adenoviral vector systems selection should match the target cell receptor profile, required transgene capacity, expression goals, and immune constraints of the application. Conventional Ad5 is effective in CAR-positive cells, while Ad5/35 and RGD-modified vectors can redirect cellular entry through CD46 or integrin-related pathways; helper-dependent adenoviral vectors remove most viral coding sequences to expand payload capacity and reduce viral gene expression. These systems support tailored applications in gene delivery, vaccines, oncolytics, and research. Start with adenoviral vector design for genome engineering, and see adenovirus packaging for the production workflow.
01 What is Ad5/35? A chimeric vector that swaps the fiber knob to target CD46 instead of CAR.
02 What is Ad5-RGD? An RGD motif in the fiber HI loop redirects entry to integrins.
03 What is HDAd? A gutless adenoviral vector retaining only ITRs and packaging Ψ with ~36 kb of capacity.
04 Which should I choose? Match the receptor profile, insert size, and immunity to the vector system.
Direct Answer
Why one adenoviral vector cannot serve every target
Ad5 enters cells primarily through the CAR receptor. Cell types with low CAR expression—including hematopoietic stem cells, endothelial cells, and certain tumors—are transduced poorly, limiting the classic vector's reach. A single serotype also faces pre-existing neutralizing immunity in much of the human population.
Engineered systems address these limits directly: chimeric and RGD-modified vectors retarget entry to alternative receptors, and helper-dependent vectors strip viral genes to enlarge capacity and dampen immunity. Choosing among them is a question of receptor biology, payload size, and immune context.
The key principle: match the vector's entry receptor and genetic payload to the target cell and application, rather than forcing a single backbone to fit every study.
Ad5
Classic CAR-Targeting Vector
The standard E1/E3-deleted Ad5 vector offers high titer and strong expression but depends on CAR expression and faces pre-existing immunity.
Ad5/35 Chimeric
CD46-Retargeted Vector
The fiber knob from Ad35 retargets entry to CD46, enhancing transduction of hematopoietic and tumor cells that express CD46 highly.
Ad5-RGD
Integrin-Binding Vector
An RGD peptide inserted in the fiber HI loop redirects entry through integrins, broadening the infection spectrum beyond CAR.
HDAd
Helper-Dependent Gutless Vector
All viral genes are removed except the ITRs and Ψ, yielding ~36 kb capacity, low immunogenicity, and prolonged expression.
System Comparison
Ad5 vs Ad5/35 vs RGD vs HDAd
Each adenoviral vector system trades tropism, capacity, immunogenicity, and production complexity differently. The table below maps those trade-offs to guide selection.
| Attribute | Ad5 | Ad5/35 Chimeric | Ad5-RGD | Helper-Dependent (HDAd) |
|---|---|---|---|---|
| Primary receptor | CAR | CD46 | Integrins (via RGD) | Retains Ad5 tropism |
| Insert capacity | ~7.5 kb | ~7.5 kb | ~7.5 kb | ~36 kb |
| Immunogenicity | Moderate-to-strong | Moderate; may evade some Ad5 immunity | Moderate | Lowest; prolonged expression |
| Best target | CAR-positive cells | CD46-high hematopoietic and tumor cells | Broad, CAR-independent spectrum | Large, long-term gene delivery |
| Production complexity | Lowest | Low | Low | Highest; requires helper virus |
Creative Biolabs builds each of these systems within a dedicated capsid-modified vector construction and helper-dependent vector program, complemented by production and characterization.
Selection Workflow
Five steps to the right vector system
Vector system selection is best approached as a sequence of questions that narrow the options from target biology down to a concrete build.
-
01
Profile the Target Cell
Confirm CAR, CD46, and integrin expression to predict which entry route will work.
-
02
Size the Payload
Match insert size and cassette number to first-generation or helper-dependent capacity.
-
03
Assess Immunity
Consider pre-existing anti-Ad5 immunity and the need to lower immunogenicity.
-
04
Select a System
Choose Ad5, Ad5/35, RGD, or HDAd based on the combined receptor and payload profile.
-
05
Validate Transduction
Confirm expression and tropism in the relevant cell or animal model before scale-up.
Engineering Variables
Control how a vector system is built
The performance of each system depends on how its targeting and payload elements are engineered. These variables determine the difference between a nominal system and one optimized for the application.
Fiber Knob Swap
Replacing the Ad5 knob with an Ad35 knob retargets entry to CD46, the basis of the Ad5/35 chimeric system.
Peptide Insertion
Inserting an RGD motif into the fiber HI loop redirects binding to integrins, broadening the infection spectrum.
Antibody Modification
Bridging antibodies or receptor ligands onto the capsid retarget the vector toward specific surface markers.
Gene Depletion
Removing all viral coding sequences leaves only ITRs and Ψ, producing the gutless HDAd with maximal capacity.
Regulated Elements
Tissue-specific or inducible promoters add spatial and temporal control on top of the chosen vector system.
Hybrid Assembly
Combining adenoviral components with other vectors (e.g., retrovirus) creates hybrid systems with merged properties.
Decision Framework
Choosing a vector system by application
Different applications favor different systems. The framework below links common goals to the adenoviral vector system that best serves them.
General overexpression
Choose Ad5: the standard, robust backbone for routine expression in CAR-positive cells.
Decision supported: adenoviral vector development.
Hematopoietic or tumor targeting
Choose Ad5/35: when CD46 is highly expressed and CAR is limiting.
Decision supported: chimeric vector construction.
Broad, CAR-independent transduction
Choose Ad5-RGD: to expand the infection spectrum through integrins.
Decision supported: peptide-incorporated construction.
Large or long-term gene delivery
Choose HDAd: for ~36 kb capacity and low immunogenicity with prolonged expression.
Decision supported: helper-dependent vectors.
Vaccines, oncolytics, and immune applications
Choose application-matched systems: from vaccine vectors to suicide-gene and immune-stimulant designs.
Decision supported: vaccine development, suicide-gene therapy, and immune-stimulant vectors.
Strategy Outputs
From system selection to deliverable vector
Each selection is converted into a built, validated vector system.
Vector system
Ad5, Ad5/35, RGD, or HDAd as selected.
Tropism profile
Documented receptor and target-cell specificity.
Payload capacity
Insert size and cassette count matched to the system.
Validation data
Transduction and expression results in relevant models.
From System to Study
Creative Biolabs Support
Creative Biolabs delivers engineered adenoviral vector systems end to end, from capsid and fiber modification through production and characterization.
02 / REGULATED
Regulated and targeting vector systems
Tissue-targeting and inducible designs—including tetracycline, hypoxia, radiation, and tumor-specific systems—for precise control.
03 / HDAD
Helper-dependent vectors
Gutless HDAd systems for large-cargo, low-immunogenicity, and long-term expression applications.
04 / APPLICATION
Vaccine and therapeutic vectors
Adenoviral vectors for vaccines, suicide-gene therapy, RNAi delivery, and immune stimulation, matched to the clinical or research goal.
05 / PRODUCTION
Production and characterization
Scalable production, purification, titration, and QC to deliver the selected vector system at the required titer and purity.
Selected Reading
Scientific context for adenoviral vector systems
Serotype Comparison
Hamilton MM, Byrnes GA, Gall JG, Brough DE, King CR, Wei LL. Alternate serotype adenovector provides long-term therapeutic gene expression in the eye. Molecular Vision. 2008;14:2537-2543. PMID: 19122827.
Helper-Free Systems
Liu J, Seol DW. Helper virus-free gutless adenovirus (HF-GLAd): a new platform for gene therapy. BMB Reports. 2020;53(11):565-575. https://doi.org/10.5483/BMBRep.2020.53.11.185.
Clinical Applications
Scarsella L, Ehrke-Schulz E, Paulussen M, Thal SC, Ehrhardt A, Aydin M. Advances of recombinant adenoviral vectors in preclinical and clinical applications. Viruses. 2024;16(3):377. https://doi.org/10.3390/v16030377.
Immunogenicity
Coughlan L. Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines. Frontiers in Immunology. 2020;11:909. https://doi.org/10.3389/fimmu.2020.00909.
FAQ
Adenoviral vector system questions
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
